Seeking Alpha

AVI BioPharma (AVII) -31.8% premarket after saying a 24-week study showed its eteplirsen drug...

AVI BioPharma (AVII) -31.8% premarket after saying a 24-week study showed its eteplirsen drug had a statistically significant effect in raising the level of a key protein, dystrophin, in boys with Duchenne muscular dystrophy, but patients given the drug for only 12 weeks showed no significant increase despite receiving higher doses. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)